Active — Not RecruitingNot Applicable

Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins

Russia100 participantsStarted 2023-04-01

Plain-language summary

The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The study will include men or women over 18 years of age with varicose disease of the lower extremities C2-C3 according to the CEAP classification, confirmed by ultrasound duplex scanning of the veins of the lower extremities Exclusion Criteria: * the presence of neoplasms, previous operations on the vessels of the lower extremities, deep vein thrombosis, severe concomitant diseases, including infectious ones, pregnancy, lactation

What they're measuring

changes in biomarkers of venous wall remodeling

Timeframe: At baseline, and at 2, 3 and 6 months after the start of treatment

Changes in biomarkers expression in venous wall

Timeframe: 6 months

Trial details

NCT IDNCT06367166

SponsorRyazan State Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-01

View on ClinicalTrials.gov More Varicose Veins of Lower Limb trials